Rebecca Silbermann
- Hematology top 2%
- Molecular Biology
- Oncology top 5%
- Ecology
- Genetics
- Co-authors
- G. David RoodmanMarc TatarDeborah L. GalsonParameswaran HariEva MedvedovaKelly GodbySaurabh ChhabraNatalie S. Callander
- Topics
- Multiple Myeloma Research and Treatments (47 papers)Bone health and treatments (14 papers)Protein Degradation and Inhibitors (12 papers)
- Cited by
- HematologyAgingOncology
- Journals
- Journal of Clinical OncologySHILAP Revista de lepidopterologíaBlood
- Partner nations
- United StatesItalyUnited Kingdom
In The Last Decade
Rebecca Silbermann
54 papers receiving 1.1k citations
Peers
Comparison fields: 5 of 94
- Hematology 606
- Molecular Biology 600
- Oncology 488
- Ecology 84
- Genetics 76
Countries citing papers authored by Rebecca Silbermann
This map shows the geographic impact of Rebecca Silbermann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rebecca Silbermann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rebecca Silbermann more than expected).
Fields of papers citing papers by Rebecca Silbermann
This network shows the impact of papers produced by Rebecca Silbermann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rebecca Silbermann. The network helps show where Rebecca Silbermann may publish in the future.
Co-authorship network of co-authors of Rebecca Silbermann
This figure shows the co-authorship network connecting the top 25 collaborators of Rebecca Silbermann. A scholar is included among the top collaborators of Rebecca Silbermann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rebecca Silbermann. Rebecca Silbermann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 2 | |
| 3 | 0 | |
| 4 | 1 | |
| 5 | 2 | |
| 6 | 71 | |
| 7 | 0 | |
| 8 | 146 | |
| 9 | 2 | |
| 10 | 1 | |
| 11 | 1 | |
| 12 | 5 | |
| 13 | EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation | 1 |
| 14 | 4 | |
| 15 | 34 | |
| 16 | 57 | |
| 17 | Myeloma bone disease: Pathophysiology and management. | 7 |
| 18 | 39 | |
| 19 | 1 | |
| 20 | 74 |
About Rebecca Silbermann
Rebecca Silbermann is a scholar working on Hematology, Aging and Oncology, having authored 59 papers that have together received 1.1k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (47 papers), Bone health and treatments (14 papers) and Protein Degradation and Inhibitors (12 papers). The work is most often cited by research in Hematology (606 citations), Aging (42 citations) and Oncology (488 citations). Rebecca Silbermann has collaborated with scholars based in United States, Italy and United Kingdom. Frequent co-authors include G. David Roodman, Marc Tatar, Deborah L. Galson, Parameswaran Hari, G. David Roodman, Eva Medvedova, Kelly Godby, Saurabh Chhabra, Natalie S. Callander and Luciano J. Costa. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.